Evotec wins grant to advance H3 receptor antagonist

pharmafile | May 4, 2010 | News story | Research and Development CNS, Evotec, MS 

Evotec is to receive funding of up to 1.5 million euros from a German government fund to advance its H3 receptor antagonist programme into the clinic.

Using its CNS expertise coupled with its leading discovery platform, Evotec has identified and optimised H3 receptor antagonists through to pre-clinical development. This grant will help fund the programme through phase I trials.

The histamine H3 receptor is a drug target of high interest because of evidence that blocking this receptor in the brain can improve cognition, alertness and attention.

H3 receptor antagonists could become a new therapy class in a numerous CNS indications, including excessive fatigue associated with conditions such as multiple sclerosis.

Evotec won the grant as part of the Neu2 consortium, which focuses on developing drugs for multiple sclerosis and other neurodegenerative diseases.

Other consortium members includes Merck Serono, the European ScreeningPort, Bionamics, and the University Medical Center Hamburg-Eppendorf.

The grant was organised by Germany’s Federal Ministry of Education and Research (BMBF) to support innovative drug discovery programmes in the German pharma and biotech industry.

Related Content

Evotec and Dewpoint Therapeutics enter strategic partnership

Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s …

Pharmanovia acquires CNS portfolio from Sanofi

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a …

robina-weermeijer-ihfopazzjhm-unsplash_5

FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS

Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its …

Latest content